

Supporting Information

Biosynthetic crossover of 5-lipoxygenase and cyclooxygenase-2 yields 5-hydroxy-PGE₂ and 5-hydroxy-PGD₂

Fumie Nakashima¹, Takashi Suzuki¹, Odaine N. Gordon¹, Dominic Golding¹, Toshiaki Okuno², Juan A. Giménez-Bastida¹, Takehiko Yokomizo², and Claus Schneider¹

¹Division of Clinical Pharmacology, Department of Pharmacology, and Vanderbilt Institute of Chemical Biology, Vanderbilt University Medical School, Nashville, TN 37232, U.S.A.

²Department of Biochemistry, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan

Table of Contents

General Information	p. 2
Experimental Procedures	p. 2
Supplementary Figures	p. 6
Supplementary Tables	p. 12
NMR Spectra	p. 18

General Information

Materials. Prostaglandin standards (PGD₂, PGE₂, PGF_{2α}, PGF_{2β}, 11β-PGF_{2α}), NS-398, and indomethacin were obtained from Cayman Chemical. Other reagents and solvents were obtained from Acros, Fischer, Sigma-Aldrich, or TCI America. Recombinant human COX-2 (1) and recombinant human H-PGDS (2) were expressed and purified as described. 5S-HETE was prepared from arachidonic acid according to a described procedure (3,4).

HPLC. Samples were analyzed using an Agilent 1200 HPLC system equipped with a diode array detector. RP-HPLC used a Waters Symmetry 5-μm column (4.6 x 250 mm). Solvents A (water/acetonitrile/HOAc 80/20/0.01, by vol.) and B (water/acetonitrile/HOAc 20/80/0.01, by vol.) were mixed to generate linear gradients for elution (1 ml/min flow rate).

Spectroscopy. NMR spectra were recorded using a Bruker AV-II 600 MHz spectrometer equipped with a cryoprobe. Chemical shifts (δ value) are given relative to the residual protiated solvent and are reported in parts per million (ppm). Coupling constants (J) are given in Hertz (Hz). Pulse frequencies were taken from the Bruker library. UV spectra were recorded during on-line HPLC-diode array analyses using an Agilent 1200 system or off-line using a Perkin Elmer PE-35 spectrophotometer. The LC-MS instrument was a Thermo Scientific TSQ Vantage triple stage quadrupole mass spectrometer. LC-mass spectra were recording using electrospray ionization and detection in the negative ion mode. Instrument and ionization parameters were optimized by infusion of a solution of PGD₂. For high-resolution mass spectrometry an LTQ Orbitrap 3 XL system (Thermo Scientific) was used.

Safety Statement. No unexpected or unusually high safety hazards were encountered.

Naming of Compounds. Known compounds are identified by their trivial names. The novel 5-hydroxy-prostaglandins have been named in accord with their arachidonic acid-derived analogues.

Experimental Procedures

Singlet oxidation of PGD₂ and PGE₂

Reactions appeared to give higher overall yield when conducted in multiple small aliquots in parallel rather than combined into a single large reaction. PGD₂ or PGE₂ (100 μg each) were placed in conical 1 mL glass vials containing 75 μg methylene blue (from a 5 mg/ml stock solution in methanol) in a total volume of 100 μL methanol. The vials were placed on a sheet of aluminum foil on ice. A desk lamp with a 100 W bulb was placed about 20 cm above the vials and served as the light source. For reaction times >10 h light exposure was interrupted and samples were stored in a freezer overnight before re-starting the reaction. Reaction progress was monitored by analyzing 1 μL aliquots by RP-HPLC using a Waters Symmetry C18 5 μm-column, 250 x 4.6 mm, eluted with a solvent of acetonitrile/water/acetic acid (37.5/62.5/0.01, by vol.) at 1 mL/min flow rate and UV detection using an Agilent 1200 diode array detector. After about 10-20% conversion to products (for PGE₂: 17 h; for PGD₂: 4 h) an excess of TPP was added, and the solvent was evaporated to 50 μL volume under a

stream of nitrogen. The residue was dissolved in 1 mL of ethyl acetate to remove excess methylene blue that has limited solubility that solvent, transferred to a new vial and evaporated. Products were isolated by RP-HPLC using a Waters Symmetry C18 5 μm -column, 450 x 4.6 mm, eluted with acetonitrile/water/acetic acid (for PGE₂: 30/70/0.01, by vol.; for PGD₂: 25/75/0.01, by vol.) at 1 mL/min flow rate. The collected products were evaporated to remove the organic solvent, diluted with water, and extracted using a 30 mg Waters HLB cartridge.

Methyl esterification

A solution of diazomethane in ether (2 drops, ca. 20 μL) was added to 20 μg of 5-OH-PG or 5-HETE dissolved in 20 μL of acetonitrile. The sample was mixed and immediately evaporated under a stream of nitrogen.

Derivatization with (-)-menthyl chloroformate

(-)-Menthoxycarbonyl derivatives were prepared by treatment of methyl-esterified 5-OH-eicosanoids in 40 μL of dry benzene and 12 μL of pyridine with 60 μL of a solution containing 1 $\mu\text{mol}/\mu\text{L}$ (-)-menthyl chloroformate in toluene at room temperature for 18 h. Samples were diluted with 2 mL of water, and the mixture was acidified by adding HCl. The mixture was extracted twice with 500 μL of methylene chloride and evaporated to dryness under a stream of nitrogen. The residue was dissolved in chloroform for ozonolysis.

Oxidative ozonolysis

Ozonolysis was performed by bubbling O₃ into a solution of the (-)-menthoxycarbonyl derivatives dissolved in 0.5 mL of chloroform at -20°C for 1.5 h. After the reaction, the solvent was evaporated under a stream of nitrogen, and the sample was treated with 1 mL of glacial acetic acid containing 30% hydrogen peroxide at 50°C for 18 h. The sample was diluted with 3 mL of water and extracted using a 30 mg Waters HLB cartridge. Products were eluted using methanol, evaporated, and dissolved in 50 μL acetonitrile/water 1:1 (by vol.) for LC-MS analysis.

Reduction of PGD₂ and PGE₂

PGD₂ and PGE₂ dissolved in PBS (500 nM, 1 mL) were reduced by addition of 20 μL of 1 M NaBH₄ in 0.1 N NaOH. After 5 min reaction at room temperature the samples were acidified with acetic acid (pH 4). The products were recovered by extraction using a 30-mg Waters HLB cartridge. Products were eluted from the cartridge using 0.25 mL of ethyl acetate and 1 mL of methanol and evaporated under a stream of nitrogen.

Derivatization with AMPP

Products formed in leukocyte incubations were derivatized with N-(4-aminomethylphenyl)pyridinium (AMPP) to increase sensitivity using positive ion LC-MS analysis (5). The eluates from the HLB cartridges were evaporated under a stream of nitrogen, and the following reagents were added: 10 μ L of ice-cold acetonitrile/dimethylformamide (4:1, v/v), 10 μ L of 1-ethyl-3-(3-dimethylamino-propyl) carbodiimide (640 mM in water), and 20 μ L of a solution containing 5 mM N-hydroxybenzotriazole and 15 mM AMPP (in acetonitrile). Sample tubes were briefly vortex mixed and incubated at 60°C for 30 min. The samples were diluted with 40 μ L of acetonitrile/water (1:1, v/v) and analyzed using LC-MS on the same day while maintained at 4°C in the autosampler during analysis.

LC-MS analysis

Products formed by the reaction of recombinant human COX-2 with 5-HETE (Fig. 1), samples treated with SnCl₂ (Fig. 2A) and NaBH₄ (Fig. 4) were analyzed using a Thermo TSQ Vantage triple quadrupole MS instrument (Mass Spectrometry Core, Vanderbilt University) equipped with a heated electrospray interface operated in negative ion mode. The instrument parameters were optimized by infusion of a solution of PGD₂ in acetonitrile/water 1:1 (by vol.). The electrospray needle was maintained at 4.0 kV. The ion transfer tube was operated at 300°C. A Zorbax Eclipse Plus C18 1.8- μ m column (2.1 x 50 mm; Agilent Technologies, Santa Clara, CA, USA) was used for the separation. Water and acetonitrile containing 0.01% formic acid were the mobile phases (A and B, respectively) used at a flow rate of 0.4 mL/min. Samples were analyzed in negative ion mode, and a linear gradient was used starting with 80% of solvent A, reaching 40% of solvent B at 4 min. Samples were analyzed in the negative ion Full Scan mode. The signal intensities obtained for each ion chromatogram are given in exponential format with the maximum intensity set as 100%. Data acquisition and spectral analysis were performed using Thermo Scientific Xcalibur software.

Hematin treated samples (Fig. 2B and 2C) and leukocyte samples (Fig. 5) were analyzed using a Thermo TSQ Quantis Triple Quadrupole MS instrument (Mass Spectrometry Core, Vanderbilt University) equipped with a heated electrospray interface operated in negative ion mode. A Zorbax Eclipse Plus C18 1.8- μ m column (2.1 x 50 mm; Agilent Technologies, Santa Clara, CA, USA) was used for the separation. Water and acetonitrile containing 0.01% formic acid were the mobile phases (A and B, respectively) used at a flow rate of 0.4 mL/min. For the hematin-treated sample, a linear gradient was used starting with 100% of solvent A, reaching 50% of solvent B at 4 min. For the leukocyte samples a linear gradient was used starting with 95% of A, reaching 50% of B at 4 min,

100% of B at 4.5 min, and held for 0.8 min. Data acquisition and spectral analysis were performed using Thermo Scientific Xcalibur software.

The following transitions were recorded in the selected reaction monitoring (SRM)-positive ion mode for AMPP-derivatized compounds: HKD₂ *m/z* 567->369 (+ 35 eV), HKE₂, *m/z* 567->381 (+ 35 eV); 5-OH-PGD₂ *m/z* 535->183 (+ 42 eV); 5-OH-PGE₂ *m/z* 353->183 (+ 45 eV); hexa-hydroxy C20:2 *m/z* 571->341 (+ 45 eV); 5-OH-PGF₂ *m/z* 537->183 (+ 45 eV).

References

1. Schneider, C., Boeglin, W. E., and Brash, A. R. (2004) Identification of two cyclooxygenase active site residues, leucine-384 and glycine-526, that control carbon ring cyclization in prostaglandin biosynthesis. *J. Biol. Chem.* **279**, 4404-4414
2. Griesser, M., Suzuki, T., Tejera, N., Mont, S., Boeglin, W. E., Pozzi, A., and Schneider, C. (2011) Biosynthesis of hemiketal eicosanoids by cross-over of the 5-lipoxygenase and cyclooxygenase-2 pathways. *Proc. Natl. Acad. Sci. U.S.A.* **108**, 6945-6950
3. Corey, E. J., and Hashimoto, S. (1981) A practical process for large-scale synthesis of (S)-5-hydroxy-6-trans-8,11,14,cis-eicosatetraenoic acid (5-HETE). *Tetrahed. Lett.* **22**, 299-302
4. Griesser, M., Boeglin, W. E., Suzuki, T., and Schneider, C. (2009) Convergence of the 5-LOX and COX-2 pathways. Heme-catalyzed cleavage of the 5S-HETE-derived di-endoperoxide into aldehyde fragments. *J. Lipid Res.* **50**, 2455-2462
5. Bollinger, J. G., Thompson, W., Lai, Y., Oslund, R. C., Hallstrand, T. S., Sadilek, M., Turecek, F., and Gelb, M. H. (2010) Improved sensitivity mass spectrometric detection of eicosanoids by charge reversal derivatization. *Anal. Chem.* **82**, 6790-6796

Supplementary Figures




Fig. S1. Products from singlet oxidation of PGD₂ and PGE₂. RP-HPLC analysis of (A) PGD₂ and (B) PGE₂ reacted with methylene blue in methanol under a 100 W light bulb on ice for 4 h or 17 h, respectively. Samples were reduced with an excess of triphenylphosphine and injected on a Waters Symmetry C18 5 μ m-column, 450 x 4.6 mm, eluted with acetonitrile/water/acetic acid (30/70/0.01, by vol. in panel A and 25/75/0.01, by vol. in panel B) at 1 ml/min flow rate and UV detection at 205 nm. The equivalent of 100 μ g starting material was injected.




Fig. S2. Analysis of the configuration of C-5 of 5-OH-PGD₂ and 5-OH-PGE₂ diastereomers prepared by singlet oxidation of the respective prostaglandin precursor. (A) Transformation of 5*S*- and 5*R*-HETE standards and isolated 5-OH-PGs to diastereomeric 2*R*- and 2*S*-(-)-menthoxy carbonyl (MC) 2-hydroxy-1,6-hexanedioic acid-6-methyl esters. (B) LC-MS negative ion traces (*m/z* 357.4) of (-)-MC-derivatized 2*S*- and 2*R*-hydroxy-1,6-hexanedioic acid-6-methyl ester formed upon methyl esterification (CH₂N₂), (-)-MC derivatization, and oxidative ozonolysis of 5-HETE enantiomers of known configuration and of 5-OH-PG diastereomers **3**, **4**, **5**, and **8**.

Samples were analyzed using a Waters Xevo TQ-S MS instrument (Eicosanoid and Neurochemistry Core, Vanderbilt University) equipped with a heated electrospray interface operated in negative ion mode. The instrument parameters were optimized by infusion of a solution of PGD₂ in acetonitrile/water 1:1 (by vol.). A Zorbax Eclipse Plus C18 1.8- μ m column (2.1 x 50 mm; Agilent Technologies, Santa Clara, CA, USA) was used for the separation. Water and acetonitrile containing 0.1% formic acid were the mobile phases (A and B, respectively) used at a flow rate of 0.5 ml/min. A linear gradient was used starting with 50% of solvent A, reaching 55% of solvent B at 4.5 min. The ion traces for *m/z* 357.4 for derivatized 2*R* or 2*S*-hydroxyhexanedioic methyl ester were acquired in negative ion MS1 mode. The signal intensities obtained for each ion chromatogram are given in exponential format with the maximum intensity set as 100%. Data acquisition and spectral analysis were performed using Waters MassLynx software.




Fig. S3. Reduction of PGD₂ and PGE₂ with NaBH₄ yields three PGF₂ diastereomers that were identified by co-elution with authentic standards, PGF_{2α}, PGF_{2β}, and 11β-PGF_{2α}. Diastereomers were analyzed using LC-MS, and the ion traces for *m/z* 353 acquired in negative ion MS1 mode are shown to the right of each reaction or standard. Reduction of PGD₂ yielded PGF_{2α} as a prominent product whereas 11β-PGF_{2α} was about 5% in abundance. The same preference for reduction was assumed to have occurred with 5-OH-PGD₂. Reduction of PGE₂, in contrast, gave the expected ≈1:1 mixture of PGF_{2α} and PGF_{2β} diastereomers, showing no stereoselectivity in the reduction of this compound. Samples were analyzed using a Thermo TSQ Vantage triple quadrupole MS instrument equipped with a heated electrospray interface operated in negative ion mode. The same conditions as in Fig. 4 were used.




Fig. S4. Reduction of a crude reaction of 5-HETE with COX-2 (top) and of isolated HKE₂ (bottom) with NaBH₄ yields 5,8,9,11,12,15-hexahydroxy-eicosadienoic acid **13**. Reaction products were analyzed using LC-MS, and the ion traces for *m/z* 403 acquired in negative ion MS1 mode are shown to the right of each reaction. Samples were analyzed using a Thermo TSQ Vantage triple quadrupole MS instrument equipped with a heated electrospray interface operated in negative ion mode. The same conditions as in Fig. 4 were used.




Fig. S5. Analysis of EP1-EP4 and DP1 prostanoid receptor activation by (A) 5-OH-PGE₂ and (B) 5-OH-PGD₂ in comparison to PGE₂ and PGD₂.




Fig. S6. Analysis of TP, FP, and IP prostanoid receptor activation by 5-OH-PGE₂ and 5-OH-PGD₂ in comparison to PGE₂, PGD₂, and known receptor activators (1 μM).

Table S1: NMR chemical shifts for 5S-OH-PGD₂ (4) (600.13 MHz, CDCl₃) and 5R-OH-PGD₂ (5) (600.13 MHz, CD₃CN).

5S-OH-PGD ₂ (4)						5R-OH-PGD ₂ (5)		
Proton No.	δ ¹ H (ppm)	Multi-plicity	Coupling constant (Hz)	δ ¹³ C ^b (ppm)	HMBC	δ ¹ H (ppm)	Multi-plicity	Coupling constant (Hz)
2	2.34	t	$J_{2,3} = 7.7$	33.0	1, 3, 4	2.28	t	$J_{2,3} = 7.4$
3	1.69	m		20.0	2	1.53-1.67	m	
4	1.61-1.67 ^a	m		36.4	2, 3	1.46	dt	$J_{4,5} = 6.4; J_{4,3} = 7.9$
5	4.23	m		71.9	7	4.03	dt	$J_{5,4} = 6.2; J_{5,6} = 6.3$
6	5.72	dd	$J_{6,7} = 15.7; J_{5,6} = 6.2$	136.5	5, 7, 8	5.57	dd	$J_{6,7} = 15.3; J_{5,6} = 6.2$
7	5.83	dd	$J_{6,7} = 15.7; J_{7,8} = 7.1$	127.6	5, 6, 8	5.73	dd	$J_{7,6} = 15.7; J_{7,8} = 7.5$
8	2.76	ddd	$J_{8,12} = 11.5; J_{8,9} = 3.3; J_{8,7} = 6.8$	50.3		2.65	ddd	$J_{8,12} = 11.2; J_{7,8} = 7.7; J_{8,9} = 3.4$
9	4.48	dd	$J_{9,10b} = 3.7; J_{9,8} = 3.7$	69.9		4.31	dd	$J_{9,10a} = 4.2; J_{9,8} = 4.2$
10a	2.50	d	$J_{10a,10b} = 18.9$	46.7	8, 9, 11	2.43	dd	$J_{10a,10b} = 18.3; J_{10a,9} = 4.9$
10b	2.45	dd	$J_{10b,10a} = 18.8$ $J_{10b,9} = 4.5$	46.7	11	2.24	d	$J_{10a,10b} = 18.4$
11	(keto)			215.5		(keto)		
12	3.10	dd	$J_{8,12} = 12.1; J_{12,13} = 5.1$	51.5	13, 14	2.91	dd	$J_{8,12} = 11.9; J_{12,13} = 7.4$
13	5.62	dd	$J_{13,14} = 15.7$ $J_{13,12} = 5.5$	124.9	12, 15	5.41	dd	$J_{13,14} = 15.5; J_{13,12} = 7.4$

14	5.58	dd	$J_{14,13} = 15.7$ $J_{14,15} = 5.7$	136.4	12, 15	5.52	dd	$J_{14,13} = 15.5; J_{14,15} = 6.4$
15	4.10	dt	$J_{15,14} = 6.3; J_{15,16} = 6.3$	72.9	13	3.94	dt	$J_{15,16} = 6.7; J_{14,15} = 6.3$
16	1.48	m		36.8		1.35-1.43	m	
17, 18, 19	1.25-1.35	m		22.6/25.3/31.7	20	1.23-1.29	m	
20	0.86	t	$J_{19,20} = 6.7$	14.2	18, 19	0.87	t	$J_{19,20} = 6.7$

^a the chemical shift was estimated from the H,H-COSY experiment.

^b the chemical shift was derived from the HSQC and HMBC experiments.

Table S2: NMR chemical shifts for the 6-OH-PGD₂ diastereomers (6 and 7) (600.13 MHz, CD₃CN).

6-OH-PGD ₂ , (6)				6-OH-PGD ₂ , (7)		
Proton No.	δ ¹ H (ppm)	Multi-plicity	Coupling constant (Hz)	δ ¹ H (ppm)	Multi-plicity	Coupling constant (Hz)
2	2.33	t	$J_{2,3} = 6.7$	2.34	t	$J_{2,3} = 7.0$
3	2.25	q	$J = 6.8$	2.26	q	$J = 6.9$
4	5.61	dt	$J_{4,5} = 15.4; J_{4,3} = 6.5$	5.63	dt	$J_{4,5} = 15.5; J_{4,3} = 6.5$
5	5.48	dd	$J_{5,4} = 15.1; J_{5,6} = 6.1$	5.53	dd	$J_{5,4} = 15.4; J_{5,6} = 6.1$
6	4.13	dt	$J_{6,7} = 6.8; J_{6,5} = 6.7$	4.21	m	
7(a)	1.71	ddd	$J_{7a,7b} = 13.9; J_{7a,8} = 10.6;$ $J_{7a,6} = 7.3$	1.71	ddd	$J_{7a,7b} = 14.2; J_{7a,8} = 10.4;$ $J_{7a,6} = 3.8$
7b	1.51	ddd	$J_{7a,7b} = 13.9; J_{7b,8} = 5.8;$ $J_{7b,6} = 4.4$	1.54	ddd	$J_{7a,7b} = 13.7; J_{7b,8} = 7.7; J_{7b,6}$ $= 4.1$
8	1.98	dt	$J_{8,12} = 10.9; J_{7,8} = 4.2$	2.14 ^a	m	
9	4.38	dd	$J_{9,10a} = 4.4; J_{9,8} = 4.4$	4.40	dd	$J_{9,10a} = 4.2; J_{9,8} = 4.2$
10a	2.41	dd	$J_{10a,10b} = 18.5; J_{10a,9} = 5.2$	2.42	dd	$J_{10a,10b} = 18.4; J_{10a,9} = 5.0$
10b	2.19 ^a	m		2.21 ^a	m	
11	(keto)			(keto)		
12	2.60	dd	$J_{8,12} = 11.6; J_{12,13} = 8.6$	2.63	dd	$J_{8,12} = 11.9; J_{12,13} = 8.4$
13	5.34	dd	$J_{13,14} = 15.5; J_{13,12} = 8.3$	5.33	dd	$J_{13,14} = 15.5; J_{13,12} = 8.3$
14	5.46	dd	$J_{14,13} = 15.1; J_{14,15} = 7.0$	5.48	dd	$J_{14,13} = 15.4; J_{14,15} = 6.5$
15	3.96	dt	$J_{15,16} = 6.3; J_{14,15} = 6.5$	3.95	dt	$J_{15,16} = 6.2; J_{14,15} = 6.5$
16	1.36- 1.47	m		1.35- 1.46	m	
17, 18, 19	1.23- 1.31 ^a	m		1.23- 1.32	m	
20	0.87	t	$J_{19,20} = 6.8$	0.87	t	$J_{19,20} = 6.7$

^a the chemical shift was estimated from the H,H-COSY experiment.

Table S3: NMR chemical shifts for 5S-OH-PGE₂ (3) and 5R-OH-PGE₂ (8) (600.13 MHz, CDCl₃).

Proton No.	5S-OH-PGE ₂ (3)			5R-OH-PGE ₂ (8)		
	δ ¹ H (ppm)	Multi-plicity	Coupling constant (Hz)	δ ¹ H (ppm)	Multi-plicity	Coupling constant (Hz)
2	2.36	t	$J_{2,3} = 6.9$	2.37	t	$J_{2,3} = 6.7$
3	1.65-1.71 ^a	m		1.68-1.72 ^a	m	
4	1.46-1.52 ^a	m		1.47-1.53 ^a	m	
5	4.11-4.17	m		4.11-4.18	m	
6	5.60	dd	$J_{6,7} = 15.7; J_{5,6} = 6.5$	5.65	dd	$J_{6,7} = 15.8; J_{5,6} = 5.6$
7	5.54	dd	$J_{6,7} = 15.7; J_{7,8} = 7.0$	5.61	dd	$J_{6,7} = 15.7; J_{7,8} = 5.4$
8	2.75	dd	$J_{8,12} = 12.4; J_{7,8} = 7.0$	2.75	dd	$J_{8,12} = 12.2; J_{7,8} = 5.6$
9	(keto)			(keto)		
10a	2.81	dd	$J_{10a,10b} = 18.8$ $J_{10a,11} = 7.7$	2.81	dd	$J_{10a,10b} = 18.7$ $J_{10a,11} = 7.4$
10b	2.32	dd	$J_{10b,10a} = 18.8$ $J_{10b,11} = 9.7$	2.32	dd	$J_{10b,10a} = 18.7$ $J_{10b,11} = 9.7$
11	4.11-4.17	m		4.11-4.18	m	
12	2.52	ddd	$J_{8,12} = 12.2; J_{12,11} = 8.3;$ $J_{12,13} = 8.3$	2.57	ddd	$J_{8,12} = 12.4; J_{12,11} = 8.3;$ $J_{12,13} = 8.3$
13	5.63	dd	$J_{13,14} = 15.6$ $J_{13,12} = 8.0$	5.65	dd	$J_{13,14} = 15.6$ $J_{13,12} = 7.2$
14	5.72	dd	$J_{14,13} = 15.5$ $J_{14,15} = 6.0$	5.73	dd	$J_{14,13} = 15.4$ $J_{14,15} = 5.9$
15	4.11-4.17	m		4.11-4.18	m	
16	1.46-1.52 ^a	m		1.47-1.53 ^a	m	
17, 18, 19	1.26-1.29 ^a	m		1.25-1.29 ^a	m	

20 0.86 t $J_{19,20} = 6.6$ 0.87 t $J_{19,20} = 6.6$



^a the chemical shift was estimated from the H,H-COSY experiment.

Table S4: HR-MS analysis of 5S-OH-PGD₂, 5S-OH-PGE₂, and 5S-OH-PGF_{2α}.



Compound	<i>m/z</i> calculated ^a	<i>m/z</i> observed	δ (ppm)	Derived molecular formula
5S-OH-PGD ₂ 4	367.2126	367.2124	0.5	C ₂₀ H ₃₂ O ₆
5S-OH-PGE ₂ 3	367.2126	367.2123	0.8	C ₂₀ H ₃₂ O ₆
5S-OH-PGF _{2α} 9	369.2283	369.2279	1.1	C ₂₀ H ₃₄ O ₆

^a calculations refer to the [M-H]⁻ molecular ion.



5S-OH-PGD₂, product 4, 600 MHz, CD₃CN





5R-OH-PGD₂, product **5**, 600 MHz, CD₃CN





6-OH-PGD₂, product **6**, 600 MHz, CD₃CN



6-OH-PGD₂, product **7**, 600 MHz, CD₃CN



5S-OH-PGE₂, product **3**, 600 MHz, CDCl₃



5R-OH-PGE₂, product **8**, 600 MHz, CDCl₃

